ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) The planned clinical study will be executed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback